PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
Tytuł artykułu

Computational methods in diagnostics of chronic hepatitis C

Wybrane pełne teksty z tego czasopisma
Identyfikatory
Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
Despite the considerable progress that has recently been made in medicine, the treatment of viral infections is still a problem remaining to be solved. This especially concerns infections caused by newly emerging patogenes such as: human immunodeficiency virus, hepatitis C virus or SARS-coronavirus. There are several lines of evidence that the unusual genetic polymorphism of these viruses is responsible for the observed therapeutic difficulties. In order to determine whether some parameters describing a very complex and variable viral population can be used as prognostic factors during antiviral treatment computational methods were applied. To this end, the structure of the viral population and virus evolution in the organisms of two patients suffering from chronic hepatitis C were analyzed. Here we demonstrated that phylogenetic trees and Hamming distances best reflect the differences between virus populations present in the organisms of patients who responded positively and negatively to the applied therapy. Interestingly, the obtained results suggest that based on the elaborated method df virus population analysis one can predict the final outcome of the treatment even before it has started.
Rocznik
Strony
273--281
Opis fizyczny
Bibliogr. 27 poz., 11 rys., 1 tab.
Twórcy
autor
autor
autor
autor
  • Institute of Bioorganic Chemistry, Polish Academy of Sciences, 12/14 Noskowskiego Str., 61-704 Poznań, Poland., marekf@ibch.poznan.pl
Bibliografia
  • [1] J. Holland, K. Spindler, F. Horodyski, E. Grabau, S. Nicol, and S. Van de Pol, “Rapid evolution of RNA genomes”, Science 215, 1577–1585 (1982).
  • [2] J. Holland, J.C. DelaTorre, and D.A. Steinhauer, “RNA virus populations as quasispecies”, Genetic Diversity of RNA Viruses, Springer Verlag, 1–20 (1992).
  • [3] D.B. Smith, J. McAllister, C. Casino, and P. Simmonds, “Virus ’quasispecies’: making a mountain out of a molehill?”, J. Gen. Virol. 78, 1511–1519 (1997).
  • [4] M. Figlerowicz, M. Alejska, A. Kurzy´nska-Kokorniak, and M. Figlerowicz, “Genetic variability: the key problem in the prevention and therapy of RNA-based virus infections”, Med. Res. Rev. 23(4), 488–518 (2003).
  • [5] World Health Organization, “Global surveillance and control of hepatitis C”, J. Med Virol. 6, 35–47 (1999).
  • [6] M. Aniszewska, B. Kowalik-Mikolajewska, and S. Dobosz, “Hepatitis C – epidemiology, diagnosis and treatment in children”, Epidemic Review 55(4), 503–510 (2001), (in Polish).
  • [7] M. Bendelini, M.L. Vatteroni, F. Maggi, and M. Pistello, “Hepatitis C virus”, in Viral Hepatitis, 65–127 ed. S. Specter, Humana Press Inc., 1999.
  • [8] J B. Schwimmer andW.F. Balistreri, “Transmission, natural history, and treatment of hepatitis C virus infection in the pediatric population”, Semin. Liver Dis. 20(1), 37–46 (2000).
  • [9] G. Fattovich and S.W. Schalm, “Hepatitis C and cirrhosis”, in Hepatitis C, 241–264 eds. T.J. Liang, J.H. Hoofnagle, San Diego, Academic Press, 2000.
  • [10] A.M. Di Bisceglie, “Hepatitis C and hepatocellular carcinoma”, in Hepatitis C, 265–276 eds. T. J. Liang , J. H. Hoofnagle, San Diego, Academic Press, 2000.
  • [11] S. Crotty, D. Maag, J.J. Arnold, W. Zhong, J.Y.M. Lau, Z. Hong, R. Andino, and C.E. Cameron, “The broad – spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen”, Nature Medicine 6, 1375–1379 (2000).
  • [12] S. Crotty, C. Cameron, and R. Andino, “RNA virus error catastrophe: direct molecular test by using ribavirin”, PNAS 98, 6895–6900 (2001).
  • [13] D. Landau, J.P. Batisse, C. Van Huyen, F. Piketty, G. Bloch, L. Pialoux, J.P. Belec, P. Petite, and L. Weiss, “Efficacy and safety of combination therapy with interferon – alpha 2b and ribavirin for chronic hepatitis C”, HIV – infected patients. AIDS 14, 839–844 (2000).
  • [14] S.P. Lawrence, “Advances in the treatment of hepatitis C”, Adv. Intern. Med. 45, 65–105 (2000).
  • [15] J.G. McHutchison and T. Poynard, “Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C”, Semin. Liver Dis. 19 (Suppl 1), 57–5 (1999).
  • [16] P. Simmonds, “Hepatitis C genotypes”, in Hepatitis C, 25–51 eds. T. J. Liang , J.H. Hoofnagle, San Diego, Academic Press, 2000.
  • [17] K. Moriishi and Y. Matsuura, “Mechanisms of hepatitis C virus infection”, Antivir. Chem. Chemother 14, 285–297 (2003).
  • [18] R. Bartenschlager and V. Lohmann, “Replication of hepatitis C virus”, J. Gen Virol. 81, 1631–1648 (2000).
  • [19] D.B. Smith and S.C. Inglis, “The mutation rate and variability of eucaryotic viruses: an analytical review”, J. Gen. Virol. 68, 2729–2740 (1987).
  • [20] D.A. Steinhauer and J.J. Holland, “Direct method for quantitation of extreme polymerase error frequencies at selected single base sites in viral RNA”, J. Virol. 57, 219–228 (1986).
  • [21] P. Friebe and R. Bartenschlager, “Genetic analysis of sequences in the 3’ nontranslated region of hepatitis C virus that are important for RNA replication”, J. Virol. 76 (11), 5326–5338 (2002).
  • [22] P. Friebe, V. Lohmann, N. Krieger and R. Bartenschlager, “Sequences in the 5’ nontranslated region of hepatitis C virus required for RNA replication”, J. Virol. 75 (24), 12047–12057 (2001).
  • [23] P. Sarnow, “Viral internal ribosome entry site elements: novel ribosome-RNA complexes and roles in viral pathogenesis”, J. Virol. 77 (5), 2801–2806 (2003).
  • [24] A.J. Weiner, H.M. Geysen, C. Christopherson, J.E. Hall, T.J. Mason, G. Saracco, F. Bonino, K. Crawford, C.D. Marion, and K.A. Crawford et al., “Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections”, PNAS 89, 3468–3472 (1992).
  • [25] S. Kumar, K. Tamura, and M. Nei, “MEGA3: integrated software for molecular evolutionary genetic analysis and sequence alignment”, Briefings in Bioinformatics 5 (2004), (to be published).
  • [26] P. Farci, R Strazzera, H.J. Alter, S. Farci, D. Degioannis, A. Coiana, G. Peddis, F. Usai, G. Serra, L. Chessa, G. Diaz, A. Balestrieri, and R.H. Purcell, “Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome”, PNAS 99, 3081–3086 (2002).
  • [27] J. Bła˙zewicz, P. Formanowicz, P. K˛edziora, and P. Wojciechowski, “Parallel algorithms for evolutionary history reconstruction”, Lecture Notes in Computer Science 3019, 1138–1145 (2004).
Typ dokumentu
Bibliografia
Identyfikator YADDA
bwmeta1.element.baztech-article-BPG5-0006-0009
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.